Deucravacitinib
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome
Trial Timeline
Sep 11, 2023 → Nov 16, 2028
NCT ID
NCT05946941About Deucravacitinib
Deucravacitinib is a phase 3 stage product being developed by Bristol Myers Squibb for Sjögren's Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05946941. Target conditions include Sjögren's Syndrome.
What happened to similar drugs?
0 of 7 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06979453 | Phase 3 | Recruiting |
| NCT07256015 | Pre-clinical | Recruiting |
| NCT06869551 | Phase 3 | Recruiting |
| NCT06725264 | Phase 2 | Withdrawn |
| NCT06701513 | Pre-clinical | Recruiting |
| NCT06512337 | Pre-clinical | Recruiting |
| NCT06566768 | Phase 1 | Completed |
| NCT06258668 | Pre-clinical | Recruiting |
| NCT06476834 | Approved | Completed |
| NCT05821374 | Phase 1 | Withdrawn |
| NCT06091956 | Phase 2 | Completed |
| NCT05858645 | Approved | Recruiting |
| NCT05946941 | Phase 3 | Active |
| NCT06104644 | Pre-clinical | Active |
| NCT05701995 | Approved | Completed |
| NCT05617677 | Phase 3 | Active |
| NCT05620407 | Phase 3 | Active |
| NCT05556265 | Phase 2 | Terminated |
| NCT05478499 | Approved | Completed |
| NCT04908202 | Phase 3 | Active |
Competing Products
20 competing products in Sjögren's Syndrome